REG - Ondine Biomedical - Cambridge’s Papworth Hospital Pilots Steriwave

Ondine BiomedicalAnnouncement

Thu 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251002:nRSB7976Ba&default-theme=true

RNS Number : 7976B  Ondine Biomedical Inc.  02 October 2025

2 October 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Cambridge's Papworth Hospital Pilots Steriwave

Royal Papworth Hospital Pilots Steriwave to Advance Patient Safety in Complex
Cardiac Surgeries

Ondine Biomedical Inc. (AIM: OBI) announces that the Royal Papworth Hospital
NHS Foundation Trust, one of the world's foremost cardiothoracic centres, is
launching a pilot program with Steriwave® nasal photodisinfection therapy.
Developed in collaboration with Ondine's distribution partner, Mölnlycke
Health Care, a global provider of medical solutions, this strategic initiative
aims to enhance patient safety and surgical outcomes by addressing the
critical challenge of surgical site infections (SSIs) amid rising
antimicrobial resistance (AMR).

Royal Papworth Hospital's decision to pilot Steriwave places it among a
growing list of internationally recognized cardiac centres that are adopting
universal pre-surgical nasal photodisinfection protocols. Canada's Mazankowski
Alberta Heart Institute, an early adopter, found a 32% reduction in cardiac
SSIs over mupirocin nasal decolonisation protocols.

The Royal Papworth pilot will integrate Steriwave into cardiac surgical care
pathways as part of a broader strategy to reduce patient microbial
burden-specifically in the nose-prior to surgery to help prevent infections.
The nose is a known reservoir for multidrug resistant bacteria, viruses and
fungi that are easily transmitted and have been identified as a major source
of post-surgical infections. Steriwave is a rapid, non-antibiotic nasal
decolonisation technology that does not induce resistance. It has been
deployed in infection prevention protocols at hospitals internationally to
address the global rise in multidrug resistant infection. In vitro studies
presented at ICPIC 2022 and 2023 demonstrated 99.99% kill rates against key
pathogens associated with surgical site infections, including extensively
drug-resistant (XDR) gram-negative bacteria and ESKAPE organisms such as MRSA,
Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa (ICPIC,
2022 and 2023) and 99.9% for Candidozyma auris, the deadly fungus of growing
concern to all hospitals.

Royal Papworth Hospital is widely considered one of the world's leading
centres for cardiac and cardiothoracic care. Renowned for its excellence, the
hospital was recognized by Newsweek magazine in 2019 as one of the "World's
Best Specialized Hospitals." As the UK's largest specialist cardiothoracic
hospital, it consistently performs more heart and lung transplants than any
other facility in the country and serves as a national and international
referral centre for highly specialized procedures. Its strong partnership with
the University of Cambridge, particularly through the Heart and Lung Research
Institute, positions it at the forefront of cardiovascular and respiratory
research.

Carolyn Cross, CEO of Ondine Biomedical:

"Royal Papworth has long been at the forefront of cardiothoracic innovation,
and we are honoured to support their leadership in advancing infection
prevention. This pilot underscores our shared commitment to protecting
vulnerable patients while addressing the urgent global challenge of
antimicrobial resistance."

About Steriwave and its Mode of Action

Steriwave nasal photodisinfection is a non-invasive and painless treatment
that uses a proprietary light-activated photosensitive agent to destroy
harmful bacteria, viruses, and fungi-including antibiotic-resistant strains-in
the nasal passages. The procedure takes five minutes and, unlike antibiotics,
is effective immediately and allows the normal nasal microbiome to recover
quickly, without fostering antimicrobial resistance.

The two-step process involves applying the Steriwave formulation in the
nostrils where it electrostatically binds to microbes rather than human cells.
The area is then illuminated with safe red light to activate the formulation,
triggering an oxidative burst that physically destroys all manner of pathogens
within minutes. This rapid and overwhelming oxidative stress makes it
extremely difficult for pathogens to develop resistance, and the process stops
immediately once the light is turned off.

About Royal Papworth Hospital NHS Foundation Trust

Royal Papworth Hospital, located on the Cambridge Biomedical Campus, is the
UK's leading heart and lung hospital. It is internationally renowned for
excellence in cardiothoracic surgery, transplant, and respiratory medicine. A
designated major teaching hospital and a key national referral centre, it
plays a vital role in both clinical care and medical research. Its
relationship with the University of Cambridge as a key partner in Cambridge
University Health Partners (CUHP) strengthens this mission, as this
collaborative ecosystem is dedicated to translating groundbreaking research
into tangible benefits for patients.

 

Enquiries:

 

 Ondine Biomedical Inc.                                            www.ondinebio.com
 Carolyn Cross, CEO                                                +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                                     +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                                     +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                                  +44 (0)77 1000 5910

 

About Mölnlycke Health Care

Mölnlycke Health Care is a world-leading MedTech company that specialises in
innovative solutions for wound care and surgical procedures. Mölnlycke
products and solutions are used daily by hospitals, health care providers and
patients in over 100 countries around the world. Founded in 1849, Mölnlycke
is owned by Investor AB and headquartered in Sweden. www.molnlycke.com
(http://www.molnlycke.com)

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's Steriwave photodisinfection system has a CE mark in Europe and is
approved for nasal decolonisation in Canada, Australia, Mexico and several
other countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSWSIEEISEFS